267 related articles for article (PubMed ID: 19176272)
21. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.
Horwitz EM; Uzzo RG; Hanlon AL; Greenberg RE; Hanks GE; Pollack A
J Urol; 2003 Jun; 169(6):2153-7; discussion 2157-9. PubMed ID: 12771738
[TBL] [Abstract][Full Text] [Related]
22. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
Nobes JP; Wells IG; Khaksar SJ; Money-Kyrle JF; Laing RW; Langley SE
Prostate Cancer Prostatic Dis; 2009; 12(1):61-6. PubMed ID: 18427571
[TBL] [Abstract][Full Text] [Related]
23. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
24. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
[TBL] [Abstract][Full Text] [Related]
25. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
26. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
27. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
Denham JW; Steigler A; Wilcox C; Lamb DS; Joseph D; Atkinson C; Tai KH; Spry NA; Gleeson PS; D'Este C
Cancer; 2009 Oct; 115(19):4477-87. PubMed ID: 19691097
[TBL] [Abstract][Full Text] [Related]
28. PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?
Denham JW; Lamb DS; Joseph D; Matthews J; Atkinson C; Spry NA; Duchesne G; Ebert M; Steigler A; D'Este C
Radiother Oncol; 2009 Mar; 90(3):382-8. PubMed ID: 18992951
[TBL] [Abstract][Full Text] [Related]
29. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer.
Bellera CA; Hanley JA; Joseph L; Albertsen PC
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1357-63. PubMed ID: 19395198
[TBL] [Abstract][Full Text] [Related]
30. Predictors of mortality after prostate-specific antigen failure.
D'Amico AV; Kantoff P; Loffredo M; Renshaw AA; Loffredo B; Chen MH
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):656-60. PubMed ID: 16682147
[TBL] [Abstract][Full Text] [Related]
31. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure.
Kamat AM; Rosser CJ; Levy LB; Chichakli R; Lee AK; Cheung MR; Pisters LL
Urology; 2004 Jun; 63(6):1132-7. PubMed ID: 15183966
[TBL] [Abstract][Full Text] [Related]
32. PSA doubling time post radiation: the effect of neoadjuvant androgen ablation.
Tyldesley S; Coldman A; Pickles T;
Can J Urol; 2004 Aug; 11(4):2316-21. PubMed ID: 15460601
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
Malik R; Jani AB; Liauw SL
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
[TBL] [Abstract][Full Text] [Related]
34. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
Zapatero A; Mínguez R; Nieto S; Martín de Vidales C; García-Vicente F
Eur Urol; 2009 Apr; 55(4):902-9. PubMed ID: 18485578
[TBL] [Abstract][Full Text] [Related]
35. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
[TBL] [Abstract][Full Text] [Related]
36. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
Lamb DS; Denham JW; Joseph D; Matthews J; Atkinson C; Spry NA; Duchesne G; Ebert M; Steigler A; Delahunt B; D'Este C
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):385-91. PubMed ID: 20350786
[TBL] [Abstract][Full Text] [Related]
38. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
Higgins GS; McLaren DB; Kerr GR; Elliott T; Howard GC
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):982-9. PubMed ID: 16750310
[TBL] [Abstract][Full Text] [Related]
39. Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring.
Niblock P; Pickles T;
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):59-64. PubMed ID: 16413696
[TBL] [Abstract][Full Text] [Related]
40. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
